| Identification | Back Directory | [Name]
lithium clavulanate | [CAS]
61177-44-4 | [Synonyms]
purity 96-98%
Clavulanate LithiuM
Lithium clavulanoate
Lithium clavulanate CRS
Lithium (2R,5R,Z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2R,3Z,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid lithium salt
(2R,3Z,5β)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2β-carboxylic acid lithium salt
lithium [2R-(2alpha,3(Z),5alpha)]-3-(2-hydroxyethylidene)-4-oxa-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylate
LithiuM (2R-(2alpha,3(Z),5alpha))-3-(2-hydroxyethylidene)-4-oxa-7-oxo-1-azabicyclo(3.2.0)heptane-2-carboxylate | [EINECS(EC#)]
262-639-3 | [Molecular Formula]
C8H9NO5.Li | [MDL Number]
MFCD22666231 | [MOL File]
61177-44-4.mol | [Molecular Weight]
207.11 |
| Chemical Properties | Back Directory | [Melting point ]
>234°C (dec.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Methanol (Slightly, Heated, Sonicated), Water (Slightly) | [form ]
neat | [color ]
Light Beige to Brown | [Stability:]
Hygroscopic | [Major Application]
pharmaceutical (small molecule) | [InChI]
1S/C8H9NO5.Li/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1 | [InChIKey]
JMRXTGCDVQLAFM-JSYANWSFSA-M | [SMILES]
[Li+].N21[C@H](O\C(=C/CO)\[C@@H]2C(=O)[O-])CC1=O |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS08 | [Signal word ]
Danger | [Hazard statements ]
H360 | [Precautionary statements ]
P201-P280-P308+P313 | [Hazard Codes ]
Xn | [Risk Statements ]
63 | [Safety Statements ]
36/37 | [WGK Germany ]
3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Repr. 1B |
| Hazard Information | Back Directory | [Uses]
Clavulanate Lithium is used as an antibacterial compound against a β-lactamase producing strain of Staphylococcus aureus. | [IC 50]
β-lactam |
|
|